Targeted drug trial for rare lung cancer halted early
NCT ID NCT04926831
Summary
This study aimed to test if a drug called capmatinib, given before and after surgery, could help people with certain types of non-small cell lung cancer that have specific genetic changes. The goal was to see if the drug could shrink tumors before surgery and prevent the cancer from coming back afterward. The trial was stopped early because it was very difficult to find enough eligible participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fairfax Northern Virginia Hem Onc
Fairfax, Virginia, 22031, United States
-
Fairfax Northern Virginia Hem Onc .
Fairfax, Virginia, 22031, United States
-
UCLA Oncology Hematology
La Jolla, California, 92037, United States
-
UCLA Oncology Hematology .
La Jolla, California, 92037, United States
-
University of California Davis Cancer Center
Sacramento, California, 95817, United States
-
University of California Davis Cancer Center .
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.